PKCβ to promote the assembly of the CARD11-BCL10-MALT1 adaptor complex, which recruits and activates IκB kinase 4-6 . Genome sequencing revealed gain-of-function mutations that target the CD79A and CD79B BCR subunits and the Toll-like receptor signalling adaptor MYD88 5,7 , with MYD88(L265P) being the most prevalent isoform. In a clinical trial, the BTK inhibitor ibrutinib produced responses in 37% of cases of ABC 1 . The most striking response rate (80%) was observed in tumours with both CD79B and MYD88(L265P) mutations, but how these mutations cooperate to promote dependence on BCR signalling remains unclear. Here we used genome-wide CRISPR-Cas9 screening and functional proteomics to determine the molecular basis of exceptional clinical responses to ibrutinib. We discovered a new mode of oncogenic BCR signalling in ibrutinib-responsive cell lines and biopsies, coordinated by a multiprotein supercomplex formed by MYD88, TLR9 and the BCR (hereafter termed the My-
ibrutinib-sensitive ABC lines, one ibrutinib-insensitive ABC line, and four ibrutinib-insensitive germinal centre B cell-like (GCB) lines, as well as two multiple myeloma and one T cell lymphoma line as controls (Extended Data Fig. 1a , Supplementary Tables 1, 2 ). For each gene, we derived a gene-level statistic that we term a CRISPR screen score (CSS), which is, in essence, the number of standard deviations away from the average effect of inactivating a gene (Supplementary Table 3 , Methods).
Non-targeting control sgRNAs were not toxic, whereas sgRNAs targeting pan-essential genes 8 were depleted in all lines (Extended Data Fig. 1b ). Among genes encoding B-cell transcription factors, we observed DLBCL subtype-specific dependencies in both GCB (MEF2B, TCF3, IRF8 and SPI1) and ABC (IRF4, SPIB and BATF) cell lines (Extended Data Fig. 1c ). Results from a validation screen using approximately 10 sgRNAs per gene (Supplementary Tables 4, 5) were strongly correlated with those from the genome-wide screens (P < 0.0001; Supplementary Table 6 , Extended Data Fig. 2a ).
Most DLBCL lines depended on the BCR subunits CD79A and CD79B ( Fig. 1 ), but engaged divergent downstream survival pathways. ABC lines uniquely relied on NF-κB regulators and on JAK1/ STAT3 signalling triggered by the NF-κB-dependent cytokine IL-10. By contrast, BCR signalling in GCB lines was NF-κB-independent, but shared a dependence on PI3K/mTOR signalling with ABC cells, albeit using different signalling adapters (PIK3AP1 in ABC, CD19 in GCB). The BCR signalling mode in GCB is similar to that observed in another germinal-centre-derived malignancy, Burkitt lymphoma 9 , which was previously known as tonic signalling because it resembled tonic, NF-κB-independent BCR signalling in naive mouse B cells 10 . However, GCB and Burkitt cell lines depended on both CD19 and LYN ( Fig. 1, Extended Data Fig. 3 ), which are not required for tonic signalling in mouse B cells, so we instead term this phenomenon constitutive germinal centre BCR signalling.
The survival of BCR-dependent ABC lines relied on Toll-like receptor (TLR9), which coordinates MYD88 signalling in innate immune cells, and on two chaperones that regulate the subcellular localization of TLR9, CNPY3 and UNC93B1. TLR9 was the only essential TLR in ABC lines (Extended Data Fig. 2b ). We validated these findings using time-dependent toxicity assays in 12 DLBCL lines transduced Letter reSeArCH with vectors that co-express sgRNAs and green fluorescent protein (GFP) ( Fig. 2a ). As expected, ABC lines expressing mutant isoforms of MYD88 were sensitive to MYD88 deletion 7 . By contrast, TLR9, and its chaperones UNC93B1 and CNPY3 11 , were only essential in ABC lines with MYD88 L265P and either a CD79A or CD79B mutation. These double-mutant lines were also particularly sensitive to BTK inhibition (Supplementary Table 1 ).
We next investigated copy number and gene expression levels of TLR pathway genes in 574 DLBCL tumours 12 . ABC tumours had recurrent single copy gains or amplifications involving MYD88, TLR9, CNPY3 and UNC93B1, all of which were more highly expressed in ABC tumours and their expression correlated with copy number (Fig. 2b , Extended Data Fig. 4a , Supplementary Table 7 ). Altogether, 49.7% of ABC tumours had increased copy number of one or more of these genes ( Fig. 2b, Supplementary Table 8 ), with CNPY3 and UNC93B1 demonstrating minimal common amplified regions of 1.1 Mb and 277 kb respectively (Extended Data Fig. 4b , Supplementary Table 9 ). These data provide genetic evidence that the TLR9 pathway contributes to the ABC phenotype.
To determine TLR9 function in ABC DLBCL, we expressed a fusion protein linking TLR9 to BioID2, a promiscuous biotin ligase that biotinylates proteins within approximately 10 nm 13 . Biotinylated proteins in TLR9-BioID2-expressing ABC cells were purified and compared to proteins from control cells by SILAC (stable isotope labelling by amino acids in cell culture)-based quantitative mass spectrometry. To define the TLR9 interactome that is essential in ABC DLBCL, we compared the enrichment of each protein quantified by mass spectrometry with its respective CSS metric (Fig. 2c ). The TLR9-essential interactome confirmed the association of TLR9 with MYD88 and CNPY3, but also revealed interactions with the BCR subunits CD79A and CD79B ( Fig. 2c , Extended Data Fig. 4c-e, Supplementary Tables 10, 11 ). The IgM component of the endogenous BCR co-immunoprecipitated with TLR9 in three ABC lines more than in a GCB line ( Fig. 2d ). By contrast, neither TLR4 nor TLR7 co-immunoprecipitated with IgM (Extended Data Fig. 5a ). TLR9 associated with IgM in an intracellular fraction of ABC cells rather than a plasma membrane fraction (Extended Data Fig. 5b ), suggesting that the BCR and TLR9 might cooperate at an intracellular location.
To visualize where TLR9 and the BCR interact, we used proximity ligation assays (PLA), which identify proteins within tens of nanometres of each other 14 . An IgM-TLR9 PLA produced fluorescent puncta in the cytoplasm of ABC cells that was reduced by depletion of CD79A or TLR9 ( Fig. 2e , Extended Data Fig. 5c ). The IgM-TLR9 PLA signal was present across a panel of BCR-dependent ABC lines, with higher signals in double-mutant lines, whereas BCR-independent ABC and GCB lines had substantially lower signals (Extended Data Fig. 5d-f ). IgG-TLR9 PLA gave no detectable signal (Extended Data Fig. 5g ). IgM-TLR9 PLA signals co-localized with the endolysosomal marker LAMP1 (Extended Data Fig. 5h , i), consistent with the dependence of these ABC lines on UNC93B1 and CNPY3, which facilitate TLR9 entry into LAMP1 + endolysosomes 11 . Ectopic expression of TLR9, wild-type MYD88 or the MYD88(L265P) mutant increased the IgM-TLR9 PLA signal (Extended Data Fig. 5j ), suggesting that TLR9/MYD88 copy number gains in ABC tumours could augment BCR-TLR9 cooperation.
Knockdown of TLR9 decreased NF-κB-dependent gene expression and reduced IκB kinase activity in ABC lines with MYD88(L265P), confirming the role of TLR9 in oncogenic NF-κB signalling (Extended Data Fig. 6 ). TLR9-MYD88 PLA puncta were visible in the cytoplasm of ABC lines, but were diminished by the knockdown of TLR9, MYD88 or CD79A, suggesting that the BCR facilitates recruitment of MYD88 to TLR9 (Fig. 2f) .
These results suggest that TLR9 coordinates signalling between the BCR and MYD88. We proposed that the BCR, TLR9 and MYD88 nucleate a signallosome that activates NF-κB, which we will term the MyD88-TLR9-BCR (My-T-BCR) supercomplex. To identify additional components of the My-T-BCR supercomplex, we expressed a MYD88(L265P)-BioID2 protein in three ABC lines and performed mass spectrometry analysis of MYD88-proximal biotinylated proteins. We identified proteins biotinylated in all three lines and used their CSS scores to define the essential MYD88 interactome, which included the BCR (CD79B), mTOR, PLCγ2 and the CARD11-BCL10-MALT1 (CBM) complex ( Fig. 3a , Extended Data Fig. 7a , b, Supplementary  Tables 12-14) . Streptavidin pulldown and immunoblot analysis confirmed CARD11 and MALT1 biotinylation in ABC cells with MYD88(L265P)-BioID2 (Extended Data Fig. 7c, d) .
Finding the CBM complex in proximity to MYD88 was unexpected since these adaptors are thought to independently promote NF-κB activation. Both MALT1-MYD88 and BCL10-MYD88 PLAs yielded robust cytoplasmic puncta in ABC cells, confirming the association of endogenous MYD88 with the CBM complex ( Fig. 3b , Extended Data Fig. 7e , f). These PLA signals were reduced by knockdown of CD79A, TLR9 and CARD11, suggesting that BCR and TLR9 signalling cooperate to assemble MYD88 and the CBM into a supercomplex. Moreover, CARD11-BCL10 PLA puncta were reduced by the knockdown of TLR9 or MYD88 in double-mutant cell lines, demonstrating that TLR9 signalling controls CBM complex assembly in ABC cells ( Fig. 3d , Extended Data Fig. 7g ).
NF-κB is activated by IκB kinase (IKK)-dependent phosphorylation of IκBα. By PLA, both IgM and TLR9 associated with phosphorylated IκBα (p-IκBα) in the cytoplasm of ABC cells, which was reduced by knockdown of CD79A, TLR9 or MYD88 ( Fig. 3d, e ). Thus, NF-κB activation is closely associated with the My-T-BCR supercomplex.
We next visualized the subcellular location of the My-T-BCR supercomplex by staining ABC cells bearing MYD88(L265P)-BioID2 with fluorescently labelled streptavidin. The MYD88-BioID2 signal defined large cytoplasmic structures that co-localized with p-IKK, consistent with active NF-κB signalling at these sites ( Fig. 3f , Supplementary Video 1). These complexes extended into the cytoplasmic space from the surface of LAMP1 + vesicles. BCR was visualized by cell-surface labelling of IgM with a fluorescent Fab fragment on ice, followed by brief warming to allow internalization. The LAMP1 + vesicles with MYD88-BioID2 signals also contained IgM, suggesting a dynamic shuttling of the BCR from the plasma membrane to the intracellular site of My-T-BCR supercomplex formation.
Given that the My-T-BCR supercomplex coordinates pro-survival signalling in ABC DLBCL, we hypothesized that inhibition of BTK activity by ibrutinib might disrupt this signalling complex. Ibrutinib reduced puncta of the My-T-BCR supercomplex in ABC lines bearing MYD88(L265P)-BioID2 (Extended Data Fig. 7h ). To globally assess the effect of ibrutinib on the My-T-BCR supercomplex, we treated two ABC lines bearing MYD88(L265P)-BioID2 with ibrutinib and analysed the biotinylated proteins by mass spectrometry. Interactions of MYD88 with the CBM complex (CARD11), PLCγ2 and mTOR were disrupted by ibrutinib ( Fig. 4a , Extended Data Fig. 7i and Supplementary Tables 14, 15 ).
The ibrutinib-sensitive association of mTOR with MYD88 suggested that signalling by the My-T-BCR supercomplex might affect pathways controlled by mTOR. Of note, components of the Ragulator complex (LAMTOR1, LAMTOR3, LAMTOR4 and RRAGA), which regulates mTORC1 activity at the lysosomal membrane 15 , were biotinylated 
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by TLR9-BioID2, as were components of the lysosomal V-ATPase (ATP6V1B2 and ATP6V0D1), which regulates the mTORC1 response to amino acids 16 (Fig. 2c , Extended Data Fig. 4c , Supplementary  Tables 10, 11 ). In ABC lines with MYD88(L265P)-BioID2, mTOR localized to LAMP1 + vesicles, often in proximity to the My-T-BCR supercomplex (Fig. 4b ). PLA in three ABC lines confirmed that ibrutinib decreased association of endogenous MYD88 with mTOR, MALT1 and BCL10 ( Fig. 4c ). Ibrutinib also decreased the association of IgM and p-IκBα, but had mixed effects on IgM association with TLR9. These findings suggest that IgM trafficking to TLR9 + endolysosomes is constitutive, but interaction of the My-T-BCR supercomplex with mTOR, the CBM complex, and NF-κB is controlled by BTK-dependent BCR signalling.
Given the proximity of MYD88 and mTOR, we investigated the effect of mTOR inhibition on the My-T-BCR supercomplex. In MYD88(L265P)-BioID2-expressing ABC cells, formation of the 
My-T-BCR complex
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My-T-BCR supercomplex was reduced by ibrutinib, but was further attenuated by the addition of AZD2014, an mTORC1/2 inhibitor ( Fig. 4d ). Dual mTOR and BTK inhibition cooperatively decreased MYD88 protein levels and blocked mTOR activity, as assessed by p-4E-BP1 and p-S6 kinase, as well as NF-κB activation, as assessed by p-IKK ( Fig. 4e ). These data provide mechanistic insights into the synergism between BTK inhibitors and drugs targeting mTOR or PI3K in ABC models growing in vitro ( Fig. 4f ) and in vivo 17, 18 (Fig. 4g ).
Finally, we examined whether the My-T-BCR supercomplex is detectable in primary lymphoma biopsy samples, and if its presence might be associated with ibrutinib responsiveness. We optimized the PLA for use in formalin-fixed biopsy samples using a tissue microarray of 81 lymphoma cell lines. IgM-TLR9 PLA signals were highest in ABC lines with chronic active BCR signalling, with little if any PLA signal in other lymphoma lines or normal B cells present in tonsils or reactive lymph nodes (Extended Data Fig. 8a , b, Supplementary Table 17 ). Among DLBCL biopsies, ABC cases had significantly more IgM-TLR9 puncta than GCB cases ( Fig. 5a ). High IgM-TLR9 PLA signals were also observed in the biopsies of primary central nervous system lymphoma, Waldenström macroglobulinaemia, and its relative, lymphoplasmacytic lymphoma ( Fig. 5b ). These malignancies commonly have MYD88 L265P and/or CD79A or CD79B mutations, and respond frequently to ibrutinib [19] [20] [21] [22] [23] . Of two Waldenström macroglobulinaemia lines tested, one had My-T-BCR supercomplexes, and knockdown of the BCR (CD79A) or TLR9 was selectively toxic for this line (Extended Data Fig. 9a -c). My-T-BCR supercomplexes were not evident in mantle cell lymphoma or chronic lymphocytic leukaemia samples ( Fig. 5b ), suggesting that these malignancies rely on a qualitatively distinct form of BCR signalling.
We next examined eight available biopsies from patients with relapsed or refractory DLBCL enrolled on a clinical trial of ibrutinib monotherapy 1 . We adapted the IgM-TLR9 PLA to allow immunohistochemical identification of CD20 + lymphoma cells ( Fig. 5c ). Three ABC cases and one unclassified DLBCL scored positive in the IgM-TLR9 PLA while three other ABC cases and one GCB case were negative (see Methods; Supplementary Table 16 ). The percentage of IgM-TLR9 PLA-positive malignant cells was significantly higher (P = 0.0286) in tumours that responded to ibrutinib than in those that progressed on treatment ( Fig. 5d ). In this series, two responding cases with IgM-TLR9 puncta had CD79B or CD79A mutations, respectively, but lacked MYD88(L265P), while two other responders were wild-type for these genes ( Supplementary Table 16 ). These findings demonstrate that the My-T-BCR supercomplex exists in ABC DLBCL tumours that respond to ibrutinib, even in those lacking the MYD88 L265P CD79A or MYD88 L265P CD79B double-mutant genotype.
We provide genetic, proteomic, cell biological and functional evidence for a pro-survival signalling hub-termed the My-T-BCR supercomplex-that coordinates NF-κB activation in DLBCL and identifies tumours that respond to therapeutic inhibition of NF-κB by ibrutinib. This supercomplex is present in a subset of ABC DLBCL lines and tumours, but is generally absent from GCB DLBCL, which have an alternative 'constitutive germinal centre' BCR signalling mode, requiring distinct therapeutic strategies (Fig. 5e ). The My-T-BCR supercomplex provides mechanistic insight into the efficacy of drug combinations in ABC DLBCL and may aid in the development of predictive assays to identify patients who would benefit from drugs that target BCR-dependent NF-κB activation, including BTK inhibitors.
Online content
Any Methods, including any statements of data availability and Nature Research reporting summaries, along with any additional references and Source Data files, are available in the online version of the paper at https://doi.org/10.1038/s41586-018-0290-0.
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MEthodS
Cell culture. Cell lines were grown at 37 °C in the presence of 5% CO 2 and maintained in RPMI supplemented with fetal bovine serum (Tet tested, Atlanta Biologics,) and 1% penicillin/streptomycin and 1% l-glutamine (Invitrogen), except for OCI-Ly10 and OCI-Ly3 which were grown in IMDM supplemented with 20% heparinized human plasma, 1% penicillin/streptomycin and 55 μM β-mercaptoethanol. All cell lines were regularly tested for mycoplasma using the MycoAlert Mycoplasma Detection Kit (Lonza) and DNA fingerprinted by examining 16 regions of copy number variants (Jonathan Keats, personal communication). OCI-Ly3, although present in the database of commonly misidentified cell lines maintained by ICLAC, was included in this study as a necessary model of a BCR-independent, MYD88 L265P mutant, MYD88-dependent ABC DLBCL. This cell line was authenticated by DNA fingerprinting and compared to historical DNA controls. Cas9 vector construction. pRetroCMV/TO-Cas9-Hygro was created by ligating the tetracycline-inducible CMV promoter from pcDNA4/TO (Invitrogen) with MfeI/XbaI and blunt cloned into the XhoI/EcoRI digested pRetrosuper vector 24 . The puromycin-resistance gene from pRetroCMV/TO was removed with StuI/ ClaI and replaced with PGK-hygromycin, which was isolated from pMSCV Hygro (Clonetech) with AgeI/HindIII and similarly cloned into pRetroCMV/TO. Cas9 was isolated from the LentiCrispr v2 (Addgene 52961) and blunt cloned into pRetroCMV/TO-hygro digested with AgeI/BamHI. pCW-Cas9-Blasticidin was generated from pCW-Cas9-puro which was purchased from Addgene (50661) and digested with BamHI and XbaI to remove the puromycin resistance gene. A g-block (IDT) containing the blasticidin resistance gene was Gibson cloned into the cut vector with 12-base-pair overlaps. Cas9 clone generation. Cell lines were transduced several times with either pTO-Cas9-hygro or pCW-Cas9, selected and dilution cloned. Single-cell clones were picked and tested for functional Cas9 cutting after transduction with sgRNAs that target surface markers including CD20 or ICAM1. Clones were selected based on loss of surface expression within the transduced population as measured by FACS 8-14 days after the addition of doxycyline. sgRNA vector and cloning. The pLKO-based sgRNA vector was purchased Addgene (52628). The puromycin gene was removed and replaced with a puro-GFP fusion protein previously described 25 using Gibson assembly. The resulting plasmid was digested with BfuAI and incubated with shrimp alkaline phosphatase before isolating the backbone. Complementary sgRNA sequences flanked by ACCG on the 5′ end, and CTTT on the 3′ of the reverse strand, were annealed, diluted and ligated into the cut vector with T4 ligase according to the manufacturer's instructions. All transformations were performed in Stbl3 bacteria and grown at 30 °C. sgRNA library construction. The genome-wide Brunello sgRNA library 26 was purchased from Addgene and transformed in Stbl4 bacteria from Invitrogen. The Brunello library contains 77,441 sgRNAs targeting four unique positions in most (19, 114) protein-coding genes, along with 1,000 negative control sgRNAs. Sequences for the follow up library of 12,472 sgRNAs were chosen from published sgRNA libraries 27, 28 or were designed using the online tool at http:// crispr.mit.edu. The library (CustomArray Inc.) of 74-mer of the sgRNA sequence prepended with the oligonucleotide sequence GGAAAGGACGAAACACCG and followed by GTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGC. The oligonucleotide library was PCR amplified with Herculase II Fusion DNA polymerase (Agilent) using ArrayF and ArrayR 27 . The subsequent PCR product was gel extracted using an eGel from Invitrogen and 20 ng of library was Gibson cloned into BfuAI-cut sgRNA vector following the manufacturer's instructions. Transformations were grown at 30 °C overnight on 24.5 cm 2 bioassay plates maintaining at least 100× coverage. Colonies were scrapped, spun and DNA was isolated with Blood and Cell Culture DNA Maxi kits (Qiagen). Virus production and transduction. Lentiviruses were produced in 293FT cells by transfecting sgRNA vectors with packaging vectors pPAX2 (Addgene 12260) and pMD2.g (Addgene 12259) in a 4:3:1 ratio in serum-free Opti-MEM. Trans-IT 293T (Mirus) was added and incubated for 15 min before adding dropwise to cells. Supernatants were harvested 24, 48 and 72 h later, spun at 1,000 g to pellet any virus producing cells and then incubated with Lenti-X concentrator (CloneTech). Virus was concentrated according to manufacturer's instructions, aliquoted and frozen. Virus titration was performed on target cell populations and GFP was measured 3-4 days later. When GFP was not present in the backbone of the sgRNA plasmids, transduced cells were split and incubated with or without puromycin until untransduced control cells were dead. The percentage of viable cells was then measured by FACS and percent transduction was calculated as the ratio of viable cells in treated versus untreated wells. Pooled sgRNA screening. For both genome-wide and targeted follow-up screens, individual replicates were transduced such that an average of 500 copies of each sgRNA was present after selection. Cultures were carried for the duration of the 21-day screen maintaining 500× coverage. Antibiotic selection was started 3-4 days after transduction and carried out until untransduced control cells were dead, approximately 4-5 days later. Cells were then harvested for a day 0 time point and doxycycline was added to the culture media at 200 ng ml −1 final concentration. Transduced cells were counted and passaged every two days with fresh media containing doxycycline until day 21 when cells were again collected for DNA extraction. DNA was isolated from frozen cell pellets using Qiagen QIAmp DNA Blood Midi and Maxi kits. Library amplification, sequence extraction and PCR primers. For both screens, sgRNA sequences were amplified using a nested PCR to first isolate the sgRNA sequence from genomic DNA and then to add nextgen sequencing adapters compatible with Illumina's NextSeq500. Products were amplified using ExTaq (Takara) for 18 cycles in both rounds of amplification. Products were size selected using an eGel (Invitrogen) and libraries were quantitated using an Illumina specific Kapa quantification kit according to the manufacturer's instructions or by Qubit (Thermo Fisher Scientific). All libraries were sequenced using a high output single-read 75 cycle read flow cell. An average of 400× (200-700×) sequencing depth was achieved. Libraries were multiplexed using indexes compatible with the Illumina TruSeq HT kit with the primers below, in which 'x' denotes an 8-base-pair index and 'y' represents a variable length adaptor inserted to prevent monotemplate. In total, 8 forward primers and 12 reverse primers were used following this format, such that 96 samples could be multiplexed. BaseSpace sequence hub (https://www.basespace.illumina.com/home/index) was used to evaluate sequencing quality measures and to demultiplex sequencing reads. Sequences were aligned to the sgRNAs library allowing for a one basepair mismatch using custom scripts and Bowtie 2 version 2.2.9 with the following parameters: -p 16 -f-local -k 10-very-sensitive-local -L 9 -N 1. CRISPR screen primers. First PCR forward primer: AATGGACTATCATATG CTTACCGTAACTTGAAAGTATTTCG; first PCR reverse primer: GTAATT CTTTAGTTTGTATGTCTGTTGCTATTATG; second PCR forward primer: AATGATACGGCGACCACCGAGATCTACACxACACTCTTTCCCTACACGA CGCTCTTCCGATCTyTCTTGTGGAAAGGACGAAACACCG; second PCR reverse primer: CAAGCAGAAGACGGCATACGAGATxGTGACTG GAGTTCAGACGTGTGCTCTTCCGATCtctactattctttcccctgcactgt. PCR amplification for sgRNA library construction: ARRAY-F: TAACTTGAAAGTATT TCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCG; AR RAY-R: ACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTTGCTAT TTCTAGCTCTAAAAC. Pooled sgRNA screen analysis. CSSs were calculated using the following formulas:
Step 1. Normalize raw counts by total read counts and eliminating those sgRNAs for which m i < 100.
Step 3. Calculate log ratios (LR)
Step 4. Z-transform log ratios
Step 5. Average across replicates Step 6. For each gene g, let G g be the set of sgRNAs that represent it, and calculate the maximal pair-wise correlation between any two sgRNAs in this set.
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If for a given gene C g < 0.45 then let i g be the index of the sgRNA representing that gene that has the highest signal variance and use that as the sole representative of gene j = S Score gj i j g If C g ≥ 0.45, then proceed to steps 7 and 8.
Step 7. Average the two sgRNAs that were most correlated within gene g.
Step 8. For each i∈G g calculate
Average together those sgRNAs for which V i > 0.85 to arrive at final CSS for gene g
In which i denotes 441] For the replication sgRNA library, in which most genes had 9-10 sgRNAs per gene, we found this could be simplified by using the z-scores of the averaged log 2 fold change of all sgRNAs per gene. As described above, using the best correlated sgRNAs per gene excluded many poor performing sgRNAs, it also excluded many high performing sgRNAs that shared expected subtype-specific toxicities. Statistical significance. The statistical significance in Fig. 1 of the CSS of ABC BCR-dependent, or GCB DLBCL, compared to all other cell lines, was calculated with a two sided random variance t-test 29 for individual genes. Screen correlations were calculated using a Pearson correlation on gene-level metrics in GraphPad Prism 7.0 software on genes displayed in Extended Data Fig. 2 . FACS analysis. Cell lines were transduced with sgRNA vectors marked by GFP. Three to four days after transduction, GFP levels were measured by flow cytometry on a BD FACS Calibur using CellQuest Pro version 6.0 and analysed with FlowJo version 9. Cells were split every other day into doxycycline containing media and GFP levels were followed for 14 days and normalized to the day 0 measurement. All sgRNA and shRNA sequences are listed below. When surface proteins were targeted, knockout was validated by flow cytometry by spinning cells down, washing in FACS buffer (PBS plus 2% (v/v) FBS, 1 mM EDTA), and stained at 4 °C for 30 min in FACS buffer with fluorescently labelled antibodies: mouse anti-human CD19-APC (Biolegend SJ25C1, 1:500), mouse anti-human CD81-PE (Biolegend 5A6, 1:500), mouse anti-human IgM-APC (MHM-88), 1:400); or from Southern Biotech: goat anti-human IgG-PE (1:200). Drug sensitivity assays. DLBCL cell lines were enumerated and 10,000 cells were seeded in triplicate in a 96-well plate in fresh media. Ibrutinib (Selleck Chem) was dissolved in DMSO and equal volumes of diluted drug were added to cells to reach the indicated final concentration. Cells were cultured with drugs, which were replenished after 48 h. Metabolic activity was measured at day 4 by adding 10 μl of MTS reagent (Promega) and incubating at 37 °C for 4 h. Absorbance was measured at 490 nm using a 96-well Tecan Infinite 200 Pro plate reader. Absorbance values from media-only wells were subtracted and data were normalized to DMSO control unless otherwise stated. GR50 was calculated using the online tool GRcalculator (http://www.grcalculator.org/) 30 . Drug matrix screens and ΔBliss calculations were performed as previously described 17 . Gene expression profiling and signature enrichment. Cells were transduced with shRNAs, puro-selected and collected at indicated times after shRNA induction. RNA was isolated using RNEasy mini kits (Qiagen). Gene expression was assessed using two-colour human Agilent 4 × 44 K gene expression arrays following the manufacturers protocol. In brief, control shSC4 (control, Cy3-labelled) RNA was compared to RNA from cells with shRNAs targeting TLR9 (C4), TLR9 (D7), MyD88 (A7) or MyD88 (B3) (Cy5-labelled) at each of the indicated time points. Array elements were filtered for spot quality using Agilent Feature Extraction software version 10.7, specific genes were determined to be downregulated if the log 2 fold change (comparing control shSC4 to shRNA for TLR9) was less than −0.3 for at least three of the four time points (shTLR9) per cell line. Signature enrichment was performed as previously described 31 . In brief, downregulated genes were tested for overlap with published gene signatures in a 2 × 2 contingency table using a Fisher's exact test.
DNA copy number analysis. DLBCL DNA samples were analysed with the Affymetrix SNP6.0 array. Probe log ratios were calculated using Affymetrix Genotyping Console, and were collected into segments of similar value using circular binary segmentation (https://bioconductor.org/packages/release/bioc/ html/DNAcopy.html). These segments were assigned copy number values as previously described 32 without segment length restrictions. DNA copy number was correlated to sample gene expression using linear regressions calculated with Graphpad Prism version 7.0. Amplified regions were identified and visualized on the UCSC genome browser, Hg19. NF-κB reporters. The generation of the IκBα luciferase reporter cell line has been previously described 33 . In brief, the TMD8-IκBα cell line was transduced with indicated shRNAs, puro-selected and induced with doxycycline. Cells were collected at the indicated time points and luciferase was measured with the Dual Luciferase Reporter Assay System (Promega) on a Tecan Infinite 200 Pro plate reader. IgM co-immunoprecipitation. HBL1, TMD8, OCI-Ly10 and OCI-Ly19 cells were lysed at 10 7 cells per ml in a modified RIPA buffer (0.5% Triton X-100, 0.25% deoxycholate, 0.025% SDS, 10 mM Tris, pH 8.0, 100 mM NaCl, 10 mM EDTA, 1 mM Na 3 VO 4 , 30 mM pyrophosphate, 10 mM glycerophosphate, 1 mM AEBSF, 0.02 U ml −1 aprotinin and 0.01% NaN 3 ) for 10 min on ice. Lysates were cleared by centrifugation at 14,000 g for 20 min at 4 °C. IgM was immunoprecipitated by incubating lysates on ice for 1 h with 10 μg of biotin-labelled goat anti-human IgM (Jackson Immunoresearch), followed by the addition of 35 μl of pre-washed streptavidinagarose beads (Invitrogen) and rotated for 30 min at 4 °C. Beads were washed three times with cold 1× RIPA buffer, then solubilized by adding 2× LDS sample buffer (Invitrogen) with 1% β-mercaptoethanol and boiled for 5 min. Samples were separated on a 10% polyacrylamide gel and transferred to Immobilon-p PVDF membrane (Millipore) for western blot analysis. Membranes were probed with rabbit anti-TLR9 monoclonal XP, rabbit anti-TLR7 (Cell Signaling Technologies), rabbit anti-TLR4 (Santa Cruz Biotechnology) and goat anti-IgM-HRP (Bethyl). PLA. DLBCL cell lines were left untreated, treated with 10 nM ibrutinib, 200 nM AZD2014 or equivalent volumes of DMSO, or transduced with control shRNA (SC4) or shRNAs targeting CD79A, TLR9, MYD88, CARD11, BCL10 or MALT1, followed by puromycin (Invitrogen) selection as previously described 34 . Cells were plated onto a 15 well μ-Slide Angiogenesis ibiTreat chamber slide (Ibidi) and allowed to adhere to the surface for 30 min at 37 °C. Cells were then fixed with 4% paraformaldehyde (Electron Microscopy Sciences) for 20 min at room temperature and then washed in PBS (Invitrogen). Cellular membranes were labelled with 5 μg ml −1 WGA conjugated to Alexa Fluor 488 (Thermo Fisher Scientific) for 10 min at room temperature. Cells were permeabilized in cold methanol for 10 min, washed in PBS and then blocked in Duolink Blocking buffer (Sigma) for 30 min at room temperature. Primary antibodies were diluted in Duolink Antibody Diluent (Sigma) and incubated overnight at 4 °C (see Supplementary Table 8 ). Where appropriate, cells were counterstained with mouse anti-LAMP1 conjugated to Alexa Fluor 405 (Santa Cruz Biotechnology) with the primary antibodies. The next morning, cells were washed for 20 min in a large volume of PBS with 1% BSA, followed by addition of the appropriate Duolink secondary antibodies (Sigma), diluted and mixed according to the manufacturer's instructions. Cells were incubated for 1 h at 37 °C, after which cells were washed in TBST with 0.5% Tween-20 for 10 min. Ligation and amplification steps of the PLA were performed using the Duolink in situ Detection Reagents Orange kit (Sigma) according to the manufacturer's instructions. Following the PLA, cells were mounted in Prolong Gold mounting media with DAPI (Invitrogen). Images were acquired on a Zeiss LSM 880 Confocal microscope using Zeiss Zen Black version 2.3. Images for display and Pearson's correlation coefficients values were calculated with NIH ImageJ/ FIJI software version 2.0.0-rc-65/1.5ls 35 . PLA spots were counted in cell lines using Blobfinder version 3.2 36 . PLA scores were determined by normalizing the number of PLA spots counted in each sample to the average number of PLA spots counted in the control sample, which was set to 100. Box and whisker plots display the median PLA score with whiskers incorporating 10-90% of all data, outliers are displayed as dots.
The PLA was performed on formalin-fixed, paraffin-embedded (FFPE) tissue microarrays or biopsy samples in a similar manner. FFPE microarrays (7 μm) and patient tissue sections (4 μm) were deparaffinized in xylene and rehydrated in graded alcohol and distilled water. Heat-induced antigen retrieval was performed on tissue microarrays and tissue sections at pH 6.0 for 30 min. Slides were then placed in Tris-buffered solution and prepared for proximity ligation assay, as described above, samples were costained with mouse anti-human CD20-eFluor660 or AlexaFluor488 (L26, eBioscience). Data were analysed using Blobfinder version 3.2. Cells with 10 or more IgM-TLR9 puncta in their nucleus were removed from analysis to control for increased autofluorescence in FFPE samples. Tissue microarrays were prepared by fixing cells in neutral buffer formalin for 24 h, pelleting and resuspending in an equal volume of low-melt agarose in a 10 ml conical tube. The resulting pellet was paraffin embedded by standard protocol 37 . The resultant blocks were used to construct a cell line array (CMA) using the same approach Letter reSeArCH used for construction of a tissue microarray, with 1.00 mm needles, using a Beecher MTA-1 instrument (Beecher Instruments). Sample identifiers were removed and blinded before pathology review for PLA signal. After all data were collected, sample identifiers were revealed and samples were grouped by response to ibrutinib. BioID2 contructs. BioID2 (Addgene 80899) was appended to the C terminus of TLR9 and MYD88(L265P) using Gibson cloning techniques. MYD88(L265P)-13X-BioID2 was cloned by removing GFP from the previously described pBMN-MYD88(L265P)-VD-GFP 34 by restriction digest with StuI and NotI. BioID2 was PCR amplified with a 13X N-terminal linker and Gibson cloned as above from Addgene 80899 with the following primers: MYD88-Cterm/13X: CTGGACTCGC CTTGCCAAGGCCTTGTCCCTGCCCGGTGGAGGCGGGTCTGGAGGC; pBMN-NotI-BioID2-Cterm: CCTCTAGTGCGGCCGCTTATGCGTAATC CGGTACATC. BioID2 was also appended to the C terminus of both wild-type and mutant isoforms of MYD88 with a two-amino acid linker (VD). First, BioID2 and MYD88 were PCR amplified with Primestar (Takara) using the following primers: BioID FWD: TTGTCCCTGCCCGTCGACTTCAAGAAC CTGATCTGGCTG; BioID REV: CGCCGGCCCTCGAGGCTATGCGTAATC CGGTACATCG. MYD88 FWD: AATTCGAATTCCTGAAGGGCCACCATGC GACCCGACCGCGC; MYD88 REV: AGATCAGGTTCTTGAAGTCGACGGGCA GGGACAAGGC. TLR9 was cloned into a modified version of pBMN that expresses a 10× linker followed by BioID2 with the following oligonucleotides. TLR9 C-BioID FWD: CTGCCGGATCCGAATTCTAGCCACAATGGGTTTCTG CCGCAGCG; TLR9 C-BioID REV: CCCGACCCGCCTCCACCTACTTCGGCC GTGGGTCCCTGGC.
The PCR products were separated on a 1% agarose gel and column purified (Qiagen). Purified PCR products were mixed and added to pBMN-LYT2 vector that was linearized with StuI (New England Biolabs) and subjected to a Gibson reaction (New England Biolabs) following the manufacturer's protocol. Imaging MYD88-13X-BioID2. MYD88(L265P)-13X-BioID2 was retrovirally transduced into TMD8 cells, and then purified with anti-LYT2 beads as described above. Cells were first cultured for 16 h in 50 μM biotin. Next, cells were incubated with 1 μg ml −1 goat anti-human IgM Fab conjugated to Alexa Fluor 488 (Jackson Immunoresearch) for 90 min at 37 °C. During this incubation period, cells were plated onto a 15 μ-Slide 8 well IbiTreat chamber slides (Ibidi) for 30 min and allowed to stick to the slides. Cells were washed twice with PBS and then fixed with 4% paraformaldehyde (Electron Microscope Sciences) for 20 min and then permeabilized with cold methanol for 10 min at −20 °C. Fixed and permeabilized cells were blocked with Duolink blocking buffer (Sigma) for 30 min at room temperature. Cells were then incubated with rabbit monoclonal antibody anti-phospho-IKKα/β (Ser176/180) (Cell Signaling Technology) diluted 1:200 in PBS with 1% BSA for 2 h at room temperature, followed by two washes with BSA/PBS. Cells were then incubated with anti-rabbit F(ab')2 conjugated to Alexa Fluor 555 (Cell Signaling Technology) at 1:1,000, mouse anti-LAMP1 conjugated to Alexa Fluor 405 (Santa Cruz Biotechnology) at 1:50 and streptavidin conjugated to Alexa Fluor 647 (Biolegend) at 1:1,000, all diluted in BSA/PBS and allowed to incubate for 1 h at room temperature. Cells were then washed for 15 min in a large volume of PBS:BSA and mounted with Prolong Diamond mounting media (Invitrogen). Images were acquired on a Zeiss LSM 880 Confocal microscope. Images for display were prepared with NIH ImageJ/FIJI 35 and animations were prepared using the Imaris 3D rendering software (Bitplane). The number of BioID2 puncta and their intensity were quantified from z-stack images (1 μm slices) using Blobfinder.
In certain instances, TMD8, OCI-Ly10 and/or HBL1 cells expressing MYD88(L265P)-13X-BioID2 were also transduced with either control shRNA (SC4) or shRNAs targeting CD79A, TLR9 or MYD88, as described above. After puromycin (Invitrogen) selection, cells stained with streptavidin conjugated to Alexa Fluor 555 (Thermo Fisher Scientific) and anti-LYT2 conjugated to Alexa Fluor 647 (Biolegend). Cells were either subjected to FACS analysis, as described above, or were imaged as described above. Biotin spots or blobs were counted using Blobfinder, as for the PLA above. Likewise, these cell lines were either left untreated, treated with 10 nM ibrutinib or equivalent volumes of DMSO, and then stained and analysed in the same manner. Mass spectrometry and western blot analysis of BioID2 constructs. TLR9-10X-BioID2 pBMN-LYT2 and MYD88-13X-BioID2 pBMN-LYT2 constructs were retrovirally transduced into DLBCL cell lines, as described above. Infected cells were enriched by positive selection with LYT2 magnetic beads (Invitrogen). Cells were then grown in SILAC media, containing arginine and lysine labelled with stable isotopes or arginine and lysine, for 2 weeks before expansion to 100 × 10 6 cells. In certain cases, cells were treated with either 10 nM ibrutinib or 200 nM AZD2014 for 24 h. Then, 16 h before lysis, biotin (Sigma) was added to a final concentration of 50 μM to transduced cells. Cells were then lysed at 2.5 × 10 7 cells per ml in RIPA buffer modified for mass spectrometry analysis (1% NP-40, 0.5% deoxycholate, 50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM Na 3 VO 4 , 5 mM NaF, 1 mM AEBSF) for 10 min. on ice. Lysates were cleared by centrifugation at 14,000g for 20 min at 4 °C. Pre-washed streptavidin agarose beads (35 μl) were added to each sample; samples were then rotated at 4 °C for 2 h, then washed four times in 1× RIPA buffer, then solubilized with 4× LDS sample buffer (Invitrogen) with 1% β-mercaptoethanol, and boiled for 5 min. A fraction of lysates were also subjected to western blot analysis as described above. Western blots were probed with rabbit anti-CARD11 and rabbit anti-MALT1 (Cell Signaling Technologies) and mouse anti-MYD88 (Santa Cruz Biotechnology).
For mass spectrometry analysis, proteins were separated by one-dimensional gel electrophoresis (4-12% NuPAGE Bis-Tris Gel) and the entire lane of a Coomassie blue-stained gel was cut into 20 slices. All slices were processed as described previously 38 . After tryptic digestion of the proteins the resulting peptides were resuspended in sample loading buffer (2% acetonitrile and 0.05% trifluoroacetic acid) and were separated by an UltiMate 3000 RSLCnano HPLC system (Thermo Fisher Scientific) coupled online to a Q Exactive HF mass spectrometer (Thermo Fisher Scientific). First, peptides were desalted on a reverse phase C18 precolumn (Dionex 5 mm length, 0.3 mm inner diameter) for 3 min. After 3 min the precolumn was switched online to the analytical column (30 cm length, 75 mm inner diameter) prepared in-house using ReproSil-Pur C18 AQ 1.9 mm reversed phase resin (Dr. Maisch GmbH). Buffer A consisted of 0.1% formic acid in H 2 O, and buffer B consisted of 80% acetonitrile and 0.1% formic acid in H 2 O. The peptides eluted from buffer B (5-42% gradient) at a flow rate of 300 nl min −1 over 76 min. The temperature of the precolumn and the analytical column was set to 50 °C during the chromatography. The mass spectrometer was operated in a TopN data-dependent mode, in which the 30 most intense precursors from survey MS1 scans were selected with an isolation window of 1.6 Th for MS2 fragmentation under a normalized collision energy of 28. Only precursor ions with a charge state between 2 and 5 were selected. MS1 scans were acquired with a mass range from 350 to 1,800 m/z at a resolution of 60,000 at 200 m/z. MS2 scans were acquired with a starting mass of 110 Th at a resolution of 15,000 at 200 m/z with maximum IT of 54 ms. AGC targets for MS1 and MS2 scans were set to 1 × 10 6 and 1 × 10 5 , respectively. Dynamic exclusion was set to 20 s. Mass spectrometry data analysis. Mass spectrometry data analysis was performed using the software MaxQuant (version 1.6.0.1) linked to the UniProtKB/Swiss-Prot human database containing 155,990 protein entries and supplemented with 245 frequently observed contaminants via the Andromeda search engine 39 . Precursor and fragment ion mass tolerances were set to 6 and 20 p.p.m. after initial recalibration, respectively. Protein biotinylation, N-terminal acetylation and methionine oxidation were allowed as variable modifications. Cysteine carbamidomethylation was defined as a fixed modification. Minimal peptide length was set to seven amino acids, with a maximum of two missed cleavages. The false discovery rate (FDR) was set to 1% on both the peptide and the protein level using a forward-and-reverse concatenated decoy database approach. For SILAC quantification, multiplicity was set to two or three for double (Lys + 0/Arg + 0, Lys + 8/Arg + 10) or triple (Lys + 0/Arg + 0, Lys + 4/Arg + 6, Lys + 8/Arg + 10) labelling, respectively. At least two ratio counts were required for peptide quantification. The 're-quantify' option of MaxQuant was enabled. Data were filtered for low confidence peptides. Xenograft. All mouse experiments were approved by the National Cancer Institute Animal Care and Use Committee (NCI-ACUC) and were performed in accordance with NCI-ACUC guidelines and under approved protocols. Approved protocols allowed tumour growth below 20 mm in any dimension; no animals had tumours which exceeded these limits. Female NSG (non-obese diabetic (NOD)/ severe combined immunodeficient (SCID)/Il2rg −/− ) mice were obtained from NCI Fredrick Biological Testing Branch and used for the xenograft experiments between 6 and 8 weeks of age. TMD8 tumours were established by subcutaneous injection of 10 × 10 6 cells in a 1:1 Matrigel/PBS suspension. Treatments were initiated when tumour volume reached a mean of 200 mm 3 . Ibrutinib was prepared in PBS with 50% (v/v) DMSO and administered intraperitoneally once per day (5 mg kg −1 day −1 ). AZD2014 was prepared in deionized water with 1% (v/v) Tween 80 and administered per os once per day (15 mg kg −1 day −1 ). For ADZ2014 and ibrutinib combination, drugs were given at the same concentration and schedule as single agents. Tumour growth was monitored every other day by measuring tumour size in two orthogonal dimensions and tumour volume was calculated by the following equation: tumour volume = (length × width 2 )/2. Treatment randomization and experimenter blinding were not possible. Sample size was estimated based on preliminary experiments. Mice were censored if they died during treatment. FFPE biopsies. All cases were needle aspirates, whole lymph node biopsies, or were obtained from surgically removed specimens. Samples were fixed in 10% buffered formalin for 18-24 h and paraffin embedded for long term storage. Samples were studied in accordance with the ethics and principles of the Declaration of Helsinki and under Institutional Review Board approved protocols from the National Cancer Institute National Institutes of Health Protocol Review Office (protocol numbers 10-C-0181, 10-CN-074 C, 00-C-133, 00-C-133) or Johns Hopkins School of Medicine (IRB00154052). Informed consent was obtained from all patients or given an IRB-waiver as archived tissue submitted for consultation to the Hematopathology Section. All samples were anonymized or de-identified for subsequent PLA analysis. shRNA and sgRNA sequences used in functional assays. shSC4 (MSMO1 ex5) CTCTCAACCCTTTAAATCTGA; shCD19 (3′ UTR) GATTCACACCTGACT CTGAAA; shCD79A (3′ UTR) GGGGCTTCCTTAGTCATATTC; shTLR9 #1 (N133) GAGCTAAACCTGAGCTACAAC; shTLR9 #2 (3′ UTR) GCACGGTGCC ACCTCCACACT; shMYD88 #1 (3′ UTR) GTACCAGTATTTATACCTCTA; shMYD88 #2 (ex3) GGCATATGCCTGAGCGTTTC; shBCL10 #2 (3′ UTR) CTGACATTGTCTCCTATATA; shCARD11 (3′ UTR) GGGGTGTGTACCA GGCTATGA; sgTLR9 #8 GACCAGGCTCCCGAAGGAAG; sgMYD88 #10 CCGGCAACTGGAGACACAAG; sgUNC93B1 #B73 TGTTGCCATACT TCACCTCG; sgCNPY3 #9 TCAGCACGTGGTTGGCGCAG. Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper. Code availability. All computer code is available at https://lymphochip.nih.gov/ local/CRISPR/. Data availability. The gene expression datasets generated for these analyses are included in the Supplementary Information, or have been deposited in Gene Expression Omnibus (GEO) under accession numbers GSE99276. Primary sequencing data and copy number analysis DLBCL cases will be made available through the NIH dbGAP system (accession numbers phs001444, phs001184 and phs000178, https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_ id=phs001444.v1.p1) and the NCI Genomic Data Commons. All CRISPR screen data, SILAC mass spectrometry, and genomic data used in the manuscript are included in the Supplementary Tables.
Extended Data Fig. 1 | CRISPR screen 
Extended Data Fig. 4 | TLR9 overexpression and association with the BCR are features of ABC DLBCL. a, Gene expression values (log 2 FPKM) values of TLR9 associated genes are shown by DLBCL subtype, ABC in blue (n = 294), GCB in orange (n = 164) and unclassified (Unc) in grey (n = 115). Gene expression data were correlated with DNA copy number and linear regression calculated for ABC samples. *P < 0.05, ***P < 0.001, linear regression (left); *P < 0.05, ***P < 0.0001, one-way ANOVA and Tukey's post test (right). b, Amplification of the UNC93B1 and CNPY3 loci (black lines, below chromosome ideogram). Minimal shared amplified regions in ABC DLBCL biopsies are bracketed and genes displayed below. c, The essential TLR9 interactome in TMD8. TLR9-BioID2 interactome determined by SILAC-based mass spectrometry (y axis) plotted by the CRISPR screen score (CSS, x axis). Bait (TLR9) is labelled in blue. Essential interactors are labelled in red, those shared with HBL1 ( Fig. 2c 
Reporting Summary
Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Figure 3c anti-SYK PLA 4D10 mouse SCBT sc-1240 C1008 1:100 From SCBT: raised against amino acids 313-339 of Syk of human origin and recommended for detection of Syk of mouse, rat and human origin by WB, IP, IF, IHC(P) and FCM. anti-Human CD20 AlexaFluor 488 counterstaining L26 mouse eBioscience 53-0202-82 4298120 1:500 From manufacturer's website: The monoclonal antibody L26 recognizes human CD20, a two transmembrane spanning protein found on precursor and mature B lymphocytes. Observed specific CD20 staining in and around germinal centers from human tissue. anti-Human CD20 eFluor 660 counterstaining L26 mouse eBioscience 50-0202-30 4311556 1:500 From manufacturer's website: The monoclonal antibody L26 recognizes human CD20, a two transmembrane spanning protein found on precursor and mature B lymphocytes. Observed specific CD20 staining in and around germinal centers from human tissue. anti-LAMP1 AlexFluor 647 PLA/counterstaining H4A3 mouse SCBT sc-20011 AF647 D1612 1:200 From SCBT: recommended for detection of LAMP-1 of mouse, rat and human origin by WB, IP, IF, IHC(P) and FCM; also reactive with additional species, including monkey. Used for imaging LAMP1 in many studies, including PMID: 29358326 anti-rabbit IgG AlexaFluor 555 secondary rabbit CST 4413S 12 1:1000 From CST: F(ab')2 fragments are prepared from goat antibodies that have been adsorbed against pooled human serum, mouse serum, plasmacytoma/hybridoma proteins and purified human paraproteins.This product has been optimized for use as a secondary antibody in immunofluorescent applications. Fluorescent anti-species IgG conjugates are ideal for flow cytometry and immunofluorescence. Cell Signaling Technology's strict quality control procedures assure that each conjugate provides optimal specificity and fluorescence. anti-mouse IgG AlexaFluor 647 secondary rabbit CST 4410S 10 1:1000 From CST:F(ab')2 fragments are prepared from goat antibodies that have been adsorbed against human IgG and human serum. anti-p-IKK-alpha/beta S176/180 counterstaining and western blot 16A6 rabbit CST 2697S 19 CLL_8 CLL accelerated 72 F 10-CN-074 C waiver CLL_9 CLL 59 M 10-CN-074 C waiver CLL_10 CLL 64 M 10-CN-074 C waiver CLL_11 CLL 44 F 10-CN-074 C waiver CLL_12 CLL 48 F 10-CN-074 C waiver Recruitment Ibrutinib treated DLBCL were recruited as previously described (doi: 10.1038/nm.3884). For PCNS, only deceased patient samples with sufficient tissue for analysis were chosen. All samples were subsequently deidentified for PLA assays. WM/LPL, MCL and CLL archival samples were submitted for consultation to the Hematopathology Section of the National Cancer Institute (NCI), National Institutes of Health (NIH) and samples were deidentified for PLA assays.
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Methodology Sample preparation
For experiments tracking GFP as a measurement of fitness over time, cells were centrifuged at 500 x g for 5 minutes, washed in PBS, and resuspended in PBS with 2% FBS, 1mM EDTA for analysis. For experiments measuring biotinylated proteins, cells were centrifuged for 5 min at 500 x g, washed in PBS, fixed at RT for 10 minutes with 4% PFA. Cells were washed twice with PBS and resuspended in 0.1% saponin with streptavidin-AlexaFluora647 for 20 minutes, washed in PBS and resuspended in PBS with 2% FBS and 1mM EDTA for analysis.
Instrument BD FACS Calibur
Software Data was collected with CellQuest Pro and analyzed with FlowJo v9 (Treestar).
Cell population abundance Generally, more than 10,000 events were collected and analyzed.
Gating strategy
Live cells were gated using FSC/SSC parameters. GFP positive cells were gated using untransduced GFP negative controls.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
